✨ Free AI Report
DBV Technologies S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research DBV Technologies S.A.
Company Research

DBV Technologies S.A.: Business Overview, Financials & Competitive Analysis

DBV Technologies S.A. scores 7/10 on the AskCyborg Cyborg Score (Strong). Emerging epicutaneous immunotherapy leader with validated EPIT platform, positive Phase 3 data, and multiple pipeline opportunities in food allergies, positioned for regulatory approval and market expansion if execution continues.

What is DBV Technologies S.A.'s industry? DBV Technologies S.A. (dbv-technologies.com) operates in Biopharmaceuticals - Immunotherapy & Allergy Treatment. AskCyborg classifies DBV Technologies S.A. under Biopharmaceuticals - Immunotherapy & Allergy Treatment in its company registry.

DBV Technologies is a French clinical-stage biopharmaceutical company pioneering epicutaneous immunotherapy (EPIT) to treat food allergies and immunological disorders. The company's flagship VIASKIN Peanut patch has c...

7/ 10Strong

Cyborg Score thesis

Emerging epicutaneous immunotherapy leader with validated EPIT platform, positive Phase 3 data, and multiple pipeline...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Immunotherapy & Allergy Treatment
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest DBV Technologies S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for DBV Technologies S.A.

AskCyborg analysts argue the bull and bear cases for DBV Technologies S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
DBV Technologies S.A. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

DBV Technologies S.A. Overview

Pro stress-test →

DBV Technologies is a French clinical-stage biopharmaceutical company pioneering epicutaneous immunotherapy (EPIT) to treat food allergies and immunological disorders. The company's flagship VIASKIN Peanut patch has completed Phase 3 trials and recently announced positive results in children aged 4-7 years, positioning it for potential market entry in a significant unmet medical need space.

Strategic Profile

Pro stress-test →

DBV leverages its proprietary Viaskin technology platform that delivers allergen immunotherapy through intact skin, avoiding systemic exposure risks. The company is expanding its pipeline with Viaskin Milk (Phase 1/2 trials) and earlier-stage programs targeting RSV vaccines, celiac disease, and inflammatory bowel disease, alongside partnerships like Nestlé Health Science for diagnostic products.

Competitive Landscape

Pro stress-test →

DBV competes in the food allergy immunotherapy space against oral immunotherapy leaders like Palforzia (Aimmune Therapeutics/Nestlé) and sublingual approaches. The EPIT patch technology differentiates DBV by targeting safety and compliance advantages, though market adoption depends on regulatory approval and physician/patient adoption relative to established oral desensitization protocols.

Industry Context

DBV Technologies S.A. operates in Biopharmaceuticals - Immunotherapy & Allergy Treatment.

Key facts

Founded: 2002 · Headquarters: Châtillon, France · Revenue: $4.15B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on DBV Technologies S.A..

  • Phase 3 VITESSE trial for VIASKIN Peanut in children ages 4-7 delivered positive topline results, de-risking lead program and supporting regulatory pathway
  • January 2026 €166.7 million warrant exercise provides substantial capital to advance development, commercialization, and pipeline expansion through inflection points
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026€166.7 million gross proceeds from full exercise of ABSA and BS warrants from March 2025 financing
  • January 2026Information filed regarding voting rights and share count as of January 31, 2026
  • +2 moreTrack every material event for DBV Technologies S.A. as it happens. Explore monitoring →
Get alerted when DBV Technologies S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

PalforziaOral immunotherapy for peanut allergy approved by FDA→Epicutaneous Immunotherapy PlatformsEmerging EPIT approaches in preclinical/early clinical stages→Sublingual ImmunotherapyAlternative route for food allergy desensitization→

Compare DBV Technologies S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

DBV Technologies S.A. operates in Biopharmaceuticals - Immunotherapy & Allergy Treatment. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Immunotherapy & Allergy Treatment research →
NEW · MCP server

Ask your AI assistant about DBV Technologies S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare DBV Technologies S.A. and its top competitor on Cyborg Score”
“What did DBV Technologies S.A. do this quarter?”
“Is DBV Technologies S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does DBV Technologies S.A. do?+
DBV Technologies is a French clinical-stage biopharmaceutical company pioneering epicutaneous immunotherapy (EPIT) to treat food allergies and immunological disorders. The company's flagship VIASKIN Peanut patch has c...
What is DBV Technologies S.A.'s Cyborg Score?+
DBV Technologies S.A. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are DBV Technologies S.A.'s main competitors?+
Named competitors include Palforzia, Epicutaneous Immunotherapy Platforms, Sublingual Immunotherapy. The full competitive landscape is in the AskCyborg report.
How can I get the full DBV Technologies S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the DBV Technologies S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track DBV Technologies S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.